Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

These are some of the best-performing stocks in the health care sector over the past month The health care sector is massive ...

Alcoholism and alcohol use disorder (AUD) are major public health and socioeconomic issues. However, a handful of ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...